Progyny, Inc. (PGNY)
| Market Cap | 1.82B -6.9% |
| Revenue (ttm) | 1.29B +6.6% |
| Net Income | 67.69M +28.9% |
| EPS | 0.76 +34.9% |
| Shares Out | 78.33M |
| PE Ratio | 30.42 |
| Forward PE | 11.29 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 945,107 |
| Open | 22.85 |
| Previous Close | 22.87 |
| Day's Range | 22.57 - 23.29 |
| 52-Week Range | 16.10 - 28.75 |
| Beta | 0.91 |
| Analysts | Buy |
| Price Target | 26.80 (+15.27%) |
| Earnings Date | May 7, 2026 |
About PGNY
Progyny, Inc., a benefits management company, provides fertility, family building, and women’s health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management s... [Read more]
Financial Performance
In 2025, Progyny's revenue was $1.29 billion, an increase of 10.40% compared to the previous year's $1.17 billion. Earnings were $58.52 million, an increase of 7.70%.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for PGNY stock is "Buy." The 12-month stock price target is $26.8, which is an increase of 15.27% from the latest price.
News
Progyny price target raised to $27 from $23 at Barclays
Barclays raised the firm’s price target on Progyny (PGNY) to $27 from $23 and keeps an Overweight rating on the shares.
KeyBanc sees modest Progyny TAM impact from DOL fertility carve-out
KeyBanc notes that the DOL has announced a proposed rule that would allow fertility treatments to be treated as a new category of “excepted benefits.” Excepted benefits sit outside the…
Progyny Transcript: Bank of America Global Healthcare Conference 2026
Strong pipeline growth, high client retention, and expanding partnerships are driving momentum, with new products and digital investments broadening the addressable market. Consistent utilization and a focus on ROI support a positive outlook, while macro trends and employer demand reinforce long-term growth.
Progyny, Inc. to Present at BofA Securities 2026 Health Care Conference
NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced that Progyny's Chief Executive Officer, Pete A...
Progyny price target raised to $31 from $30 at Citizens
Citizens analyst Constantine Davides raised the firm’s price target on Progyny (PGNY) to $31 from $30 and keeps an Outperform rating on the shares. Progyny’s Q1 revenue and EBITDA beat…
Progyny price target raised to $29 from $27 at BofA
BofA raised the firm’s price target on Progyny (PGNY) to $29 from $27 and keeps a Buy rating on the shares after “a strong quarter” that come against a backdrop…
Progyny reports Q1 adjusted EPS 50c, consensus 44c
Reports Q1 revenue $328.5M, consensus $326.51M. “We’re pleased with the strong start to the year, as member engagement trended to the higher end of our expectations, reflecting that people are…
Progyny sees Q2 adjusted EPS 50c-53c, consensus 48c
Sees Q2 revenue $342M-$355M, consensus $347.38M. Sees Q2 adjusted EBITDA $58M-$62M. The company said, “For more than a decade, Progyny (PGNY) has been meeting this need with our solutions, which…
Progyny raises FY26 adjusted EPS view to $1.98-$2.09 from $1.83-$1.95
Consensus $1.89. Narrows FY26 revenue view to $1.37B-$1.41B from $1.36B-$1.41B, consensus $1.38B. Raises FY26 adjusted EBITDA view to $232M-$244M from $224M-$239M. “This quarter’s results reflect topl...
Progyny Earnings Call Transcript: Q1 2026
Record Q1 revenue and profitability exceeded guidance, driven by strong member engagement and margin expansion. Full-year outlook raised, with double-digit growth expected excluding a former client, and robust pipeline and renewal activity supporting future growth.
Progyny, Inc. Announces First Quarter 2026 Results
Reports Record First Quarter Revenue of $328.5 MillionEarly Selling Season Activity Reflects Robust Demand for Women's Health and Family Building SolutionsReturned Value to Shareholders Through Repurc...
Progyny, Inc. Announces Details for Its First Quarter 2026 Results Report
NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, will report its financial results for the quarterly period e...
Progyny expands access to fertility, women’s health with Progyny Select
Progyny (PGNY) announces Progyny Select. Available in the U.S., Progyny Select enables small employers to have access to fertility solutions in a fixed premium model. “Progyny Select is a game-changer...
Progyny Expands Access to Fertility and Women's Health with Industry's First Fully Insured Supplemental Plan
NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announces Progyny Select, the industry's first fully i...
Progyny Commemorates 10 Years of Redefining Women's Health and Family Building Care
Throughout 2026, in partnership with members, providers, and employers, Progyny will highlight a decade of innovation, expanded access, and industry-leading outcomes. Throughout 2026, in partnership w...
Progyny price target lowered to $23 from $29 at Barclays
Barclays lowered the firm’s price target on Progyny (PGNY) to $23 from $29 and keeps an Overweight rating on the shares after meeting with management. The company sounded positive on…
Progyny Transcript: 2026 KeyBanc Capital Markets Healthcare Forum
Administrative adjustments led to a reduction in eligible lives, but utilization rates remain strong and stable. The new fully insured product targets small employers, with risk managed through data-driven underwriting and annual premium adjustments. AI and data investments are enhancing patient and provider experiences.
Progyny Transcript: Barclays 28th Annual Global Healthcare Conference
Strong client retention, stable utilization, and expanded offerings position the business for continued growth. New products target unmet needs in the fully insured market, with positive early feedback and no financial impact expected until 2027. Margin expansion is anticipated post-2026 as investments taper.
Progyny price target lowered to $19 from $26 at Canaccord
Canaccord lowered the firm’s price target on Progyny (PGNY) to $19 from $26 and keeps a Hold rating on the shares. The firm updated its model follwong Q4 results which…
Progyny Transcript: Leerink Global Healthcare Conference 2026
Utilization and consumption remained stable in 2025, with growth driven by new members and consistent treatment patterns. Strategic investments in IT, product expansion into menopause and benefit navigation, and the launch of Progyny Select are positioning the business for broader reach. Risk controls, AI-driven efficiencies, and a strong financial position support ongoing growth.
Progyny, Inc. Executives to Participate in Upcoming Investor Conferences
NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced that several members of its leadership team ...
Progyny price target lowered to $30 from $35 at BTIG
BTIG analyst David Larsen lowered the firm’s price target on Progyny (PGNY) to $30 from $35 but keeps a Buy rating on the shares after its Q4 earnings beat and…
INVO Fertility’s Wisconsin clinic joins Progyny network
INVO Fertility (IVF) announced that its Wisconsin Fertility Institute clinic has joined the Progyny (PGNY) network. Progyny provides fertility and family-building benefits to an estimated 7.2 million ...
Progyny price target lowered to $28 from $34 at Truist
Truist lowered the firm’s price target on Progyny (PGNY) to $28 from $34 and keeps a Buy rating on the shares after its Q4 results and below-consensus guide. The shortfall…
Progyny price target lowered to $28 from $32 at KeyBanc
KeyBanc analyst Scott Schoenhaus lowered the firm’s price target on Progyny (PGNY) to $28 from $32 to reflect lowered estimates, while keeping an Overweight rating on the shares. The firm…